Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05622045
Other study ID # 5220330
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date February 1, 2023
Est. completion date December 2024

Study information

Verified date June 2024
Source Loma Linda University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this observational study is to learn about the personality attributes and values of people living with obesity that are part of the Latino community, and how these personality attributes and values can help to predict success during a weight loss program. The main questions it aims to answer are: - What are the personality attributes and values of people living with obesity that sign up to the LCSS-Latino Crossover Semaglutide Study trial? - Can behavioral artificial intelligence (a computer formula) predict which patients will complete the LCSS-Latino Crossover Semaglutide Study trial? - How do behavioral artificial Intelligence predictions (a computer formula) compare to clinician predictions of patient success? - Can behavioral artificial intelligence (a computer formula) predict patient weight loss, calorie consumption and physical activity levels during the LCSS-Latino Crossover Semaglutide Study trial? Participants will be recorded in English and Spanish while responding to a question regarding participation in a weight loss study.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 59
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers
Gender All
Age group 18 Years to 74 Years
Eligibility Inclusion Criteria: - Participation in the LCSS-Latino Crossover Semaglutide Study Exclusion Criteria: - Not a participant of the LCSS-Latino Crossover Semaglutide Study at the point of data collection

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Voice data
Recorded response to a question about their participation in a weight loss study.

Locations

Country Name City State
United States Nutrition Research Center, School of Public Health, Loma Linda University Loma Linda California

Sponsors (2)

Lead Sponsor Collaborator
Loma Linda University Scaled Insights

Country where clinical trial is conducted

United States, 

References & Publications (7)

Alberga AS, Russell-Mayhew S, von Ranson KM, McLaren L. Weight bias: a call to action. J Eat Disord. 2016 Nov 7;4:34. doi: 10.1186/s40337-016-0112-4. eCollection 2016. — View Citation

Dalle Grave R, Calugi S, Compare A, El Ghoch M, Petroni ML, Tomasi F, Mazzali G, Marchesini G. Weight Loss Expectations and Attrition in Treatment-Seeking Obese Women. Obes Facts. 2015;8(5):311-8. doi: 10.1159/000441366. Epub 2015 Oct 8. — View Citation

Flint SW, Leaver M, Griffiths A, Kaykanloo M. Disparate healthcare experiences of people living with overweight or obesity in England. EClinicalMedicine. 2021 Sep 15;41:101140. doi: 10.1016/j.eclinm.2021.101140. eCollection 2021 Nov. — View Citation

Flint SW, Piotrkowicz A, Watts K. Use of Artificial Intelligence to understand adults' thoughts and behaviours relating to COVID-19. Perspect Public Health. 2022 May;142(3):167-174. doi: 10.1177/1757913920979332. Epub 2021 Jan 21. — View Citation

Hardcastle SJ, Taylor AH, Bailey MP, Harley RA, Hagger MS. Effectiveness of a motivational interviewing intervention on weight loss, physical activity and cardiovascular disease risk factors: a randomised controlled trial with a 12-month post-intervention follow-up. Int J Behav Nutr Phys Act. 2013 Mar 28;10:40. doi: 10.1186/1479-5868-10-40. — View Citation

Puhl RM, Phelan SM, Nadglowski J, Kyle TK. Overcoming Weight Bias in the Management of Patients With Diabetes and Obesity. Clin Diabetes. 2016 Jan;34(1):44-50. doi: 10.2337/diaclin.34.1.44. No abstract available. — View Citation

Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Predicted patient weight change success Predicted patient weight change as determined by Scaled Insights Behavioural Artificial Intelligence based on subject voice data. Weight loss exceeding 5-10 pounds over 6 months will be considered to be successful. Predicted weight change will be compared to the weight change measured in a separate clinical trial [Latino Crossover Semaglutide Study (LCSS) NCT05087342]. Similar weight change values between the predicted and measured outcomes will indicate that the Scaled Insights Behavioural Artificial Intelligence is good predictor. The voice data measurement will take place at baseline and take about 10-15 minutes for collection to take place.
Primary Clinician predictions Clinician (physician) judgement of patient weight loss success during a weight loss study. The clinician judgement will be measured during the second month of the subject's weight loss study.
Primary Predicated patient calorie intake Predicted patient calorie intake as determined by Scaled Insights Behavioural Artificial Intelligence based on subject voice data. Predicted calorie intake will be compared to the calorie intake measured in a separate clinical trial [Latino Crossover Semaglutide Study (LCSS) NCT05087342]. Similar calorie values between the predicted and measured outcomes will indicate that the Scaled Insights Behavioural Artificial Intelligence is good predictor. The voice data measurement will take place during the subject's initial clinic visit and take about 10-15 minutes for collection to take place.
Primary Predicated patient physical activity level Predicted patient physical activity level as determined by Scaled Insights Behavioural Artificial Intelligence based on subject voice data. Predicted physical activity will be compared to the physical activity measured in a separate clinical trial [Latino Crossover Semaglutide Study (LCSS) NCT05087342]. Similar physical activity level values between the predicted and measured outcomes will indicate that the Scaled Insights Behavioural Artificial Intelligence is good predictor. The voice data measurement will take at baseline and take about 10-15 minutes for collection to take place.
Secondary Personality attributes and values Extrapolated personality attributes and values as determined by Scaled Insights Behavioural Artificial Intelligence based on subject voice data. These are qualitative non-numerical descriptors. The voice data measurement will take place at baseline and take about 10-15 minutes for collection to take place.
Secondary Predicted patient attrition rate Predicted patient attrition rate from the weight loss study as determined by Scaled Insights Behavioural Artificial Intelligence based on subject voice data. Predicted patient attrition rate will be compared to the attrition rate occurring during the weight loss study. Similar attrition rates between the predicted and actual rates will indicate that the Scaled Insights Behavioural Artificial Intelligence is good predictor. The voice data measurement will take place at baseline and take about 10-15 minutes for collection to take place.
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2